Prelude Therapeutics (PRLD) grants 230,000 stock options to Chief Chemistry Officer

Rhea-AI Filing Summary

Prelude Therapeutics reported a stock option grant to Chief Chemistry Officer Andrew Combs. On February 4, 2026, he received an employee stock option covering 230,000 shares of common stock at an exercise price of $2.30 per share.

The option vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments (1/48 of the total shares) until fully vested, as long as Combs continues providing service to the company on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Combs Andrew

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Chemistry Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.3	02/04/2026		A		230,000		(1)	02/03/2036	Common Stock	230,000	$0.00	230,000	D

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Prelude Therapeutics (PRLD) report for Andrew Combs?

Prelude Therapeutics reported a stock option grant to Chief Chemistry Officer Andrew Combs. He received an employee stock option covering 230,000 shares of common stock, recorded as a derivative security acquisition on February 4, 2026, with direct beneficial ownership reported.

How many Prelude Therapeutics (PRLD) shares are covered by Andrew Combs’ new option?

The new employee stock option granted to Andrew Combs covers 230,000 shares of Prelude Therapeutics common stock. These shares are underlying the derivative security and represent the amount he may purchase if the option becomes fully vested and is exercised.

What is the exercise price of Andrew Combs’ stock option at Prelude Therapeutics (PRLD)?

Andrew Combs’ employee stock option has an exercise price of $2.30 per share. This price applies to each of the 230,000 underlying common shares if and when he exercises the option, subject to the vesting schedule described in the filing footnote.

When does Andrew Combs’ Prelude Therapeutics (PRLD) option start vesting and how?

The stock option begins vesting on February 4, 2027, when 25% of the total shares vest. After that date, the remaining shares vest monthly in 1/48 increments, contingent on his continued service to Prelude Therapeutics at each vesting date.

Over what period does Andrew Combs’ Prelude Therapeutics (PRLD) option fully vest?

The option is structured to vest over four years. Twenty‑five percent vests on February 4, 2027, and the remaining seventy‑five percent vests in equal monthly installments (1/48 of the total shares) until fully vested, assuming continuous service.

How many derivative securities does Andrew Combs hold in Prelude Therapeutics (PRLD) after this grant?

After the reported transaction, Andrew Combs beneficially owns 230,000 derivative securities in the form of an employee stock option. These derivative securities correspond to 230,000 underlying shares of Prelude Therapeutics common stock, held with direct ownership as of the transaction report.